BR112017011078B1 - usos de uma composição preparada a partir de kiwi ouro seco - Google Patents

usos de uma composição preparada a partir de kiwi ouro seco Download PDF

Info

Publication number
BR112017011078B1
BR112017011078B1 BR112017011078-4A BR112017011078A BR112017011078B1 BR 112017011078 B1 BR112017011078 B1 BR 112017011078B1 BR 112017011078 A BR112017011078 A BR 112017011078A BR 112017011078 B1 BR112017011078 B1 BR 112017011078B1
Authority
BR
Brazil
Prior art keywords
kiwi
composition
drug
gold
formulated
Prior art date
Application number
BR112017011078-4A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112017011078A2 (pt
Inventor
Juliet ANSELL
Paul BLATCHFORD
Original Assignee
Anagenix Ip Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anagenix Ip Limited filed Critical Anagenix Ip Limited
Publication of BR112017011078A2 publication Critical patent/BR112017011078A2/pt
Publication of BR112017011078B1 publication Critical patent/BR112017011078B1/pt

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L19/00Products from fruits or vegetables; Preparation or treatment thereof
    • A23L19/01Instant products; Powders; Flakes; Granules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
BR112017011078-4A 2014-11-28 2015-11-27 usos de uma composição preparada a partir de kiwi ouro seco BR112017011078B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NZ702454 2014-11-28
NZ70245414 2014-11-28
NZ706405 2015-03-27
NZ70640515 2015-03-27
PCT/NZ2015/050200 WO2016085356A1 (en) 2014-11-28 2015-11-27 Gold kiwifruit compositions and methods of preparation and use therefor

Publications (2)

Publication Number Publication Date
BR112017011078A2 BR112017011078A2 (pt) 2017-12-26
BR112017011078B1 true BR112017011078B1 (pt) 2021-05-11

Family

ID=56074755

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011078-4A BR112017011078B1 (pt) 2014-11-28 2015-11-27 usos de uma composição preparada a partir de kiwi ouro seco

Country Status (16)

Country Link
US (4) US10512663B2 (enExample)
EP (2) EP4548775A3 (enExample)
JP (3) JP7330667B2 (enExample)
KR (2) KR102599549B1 (enExample)
CN (3) CN116270773A (enExample)
BR (1) BR112017011078B1 (enExample)
CA (2) CA2967263A1 (enExample)
DK (1) DK3223838T3 (enExample)
ES (1) ES3023661T3 (enExample)
FI (1) FI3223838T3 (enExample)
MY (1) MY188290A (enExample)
NZ (1) NZ732197A (enExample)
PL (1) PL3223838T3 (enExample)
PT (1) PT3223838T (enExample)
SI (1) SI3223838T1 (enExample)
WO (1) WO2016085356A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2967263A1 (en) * 2014-11-28 2016-06-02 Anagenix Ip Limited Gold kiwifruit compositions and methods of preparation and use therefor
KR101833348B1 (ko) * 2016-12-26 2018-03-02 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 유방암 진단방법
KR101833504B1 (ko) * 2016-12-26 2018-03-05 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 폐암 진단방법
KR101940426B1 (ko) * 2016-12-28 2019-01-18 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 대장종양 진단 방법
KR101942197B1 (ko) * 2016-12-28 2019-01-24 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 전립선질환 진단 방법
US11413318B2 (en) * 2017-06-06 2022-08-16 Sami-Sabinsa Group Limited Compositions and methods for management of atrophic gastritis and colitis
WO2019075273A1 (en) * 2017-10-11 2019-04-18 Gu Jennifer L INTESTINAL HEALTH COMPOSITIONS
KR102130485B1 (ko) * 2017-10-13 2020-07-06 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 알츠하이머치매 진단방법
KR102007786B1 (ko) * 2017-10-18 2019-08-07 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 두경부암 진단방법
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
KR101940950B1 (ko) 2018-01-23 2019-01-21 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 담관암 진단방법
KR101944662B1 (ko) * 2018-02-14 2019-02-01 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 뇌졸중 진단방법
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
EP3846830A4 (en) 2018-09-05 2022-07-06 Solarea Bio, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES
CN109288104B (zh) * 2018-11-12 2023-09-01 方家铺子(莆田)绿色食品有限公司 一种桂圆鲜果挂黄处理设备及其处理方法
ES2884072T1 (es) 2019-01-18 2021-12-10 Cp Kelco Us Inc Composición prebiótica y su uso
CN110279814A (zh) * 2019-06-10 2019-09-27 湖北虹玮农业有限公司 一种用于中老年慢性便秘的功能食品
US11684645B2 (en) * 2019-11-26 2023-06-27 Tci Co., Ltd. Actinidia chinensis Planch ferment and use thereof
WO2022115709A2 (en) * 2020-11-30 2022-06-02 January, Inc. Methods and composition for treating metabolic syndrome
US20220233151A1 (en) * 2021-01-22 2022-07-28 Ethicon Llc Bariatric surgery post-surgical monitoring
KR102543549B1 (ko) * 2021-01-26 2023-06-15 주식회사 다솔마임마케팅사업부 칼라만시 발포정 및 그 제조 방법
CN113521109A (zh) * 2021-06-28 2021-10-22 广州知易生物科技有限公司 解纤维素拟杆菌在预防和/或治疗炎症性肠病中的应用
US12343366B2 (en) * 2021-11-05 2025-07-01 Tci Co., Ltd. Prebiotic composition and method for improving intestinal health using the same
CN116076711A (zh) * 2021-11-05 2023-05-09 百岳特生物技术(上海)有限公司 益生质组合物及其用途
AU2022391767A1 (en) 2021-11-22 2024-07-04 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
JP7701899B2 (ja) * 2022-09-14 2025-07-02 花王株式会社 クロロゲン酸類吸収量の予測方法
KR102536627B1 (ko) * 2022-09-30 2023-05-30 (주)바이텍 키위 발효물을 포함하는 알코올성 간손상 예방 또는 개선용 조성물
US20250195588A1 (en) * 2023-12-18 2025-06-19 First Day Life, Inc. Ingestible Nutritive Compositions With Prebiotics, Probiotics, and Postbiotics
US20250195594A1 (en) * 2023-12-18 2025-06-19 First Day Life Inc. Ingestible Nutritive Compositions With Prebiotics, Probiotics, and Postbiotics
NL2038369B1 (en) * 2024-07-31 2025-03-06 Sunbird Company Ltd A composition of natural kiwifruit powder and postbiotics and its use in constipation improvement

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US22355A (en) 1858-12-21 sherwood
JP2750767B2 (ja) * 1990-02-21 1998-05-13 雪印乳業株式会社 新規糖アルコール
NZ235972A (en) 1990-11-06 1995-04-27 Amaranathan Balasingham Fruit product by soft pulping after skin removal
CN1107308A (zh) * 1994-02-25 1995-08-30 中国癌症研究基金会 猕猴桃天然营养口服液
JPH10313822A (ja) 1997-05-20 1998-12-02 Pola Chem Ind Inc 腸内細菌叢改善剤及びそれを含有する組成物
AT503521A1 (de) * 2006-05-05 2007-11-15 Omnica Gmbh Verwendung eines extraktes von kiwi-frucht
NZ554991A (en) * 2007-05-03 2009-11-27 Vital Food Processors Ltd Powdered kiwifruit extract compositions for the treatment of digestive dysfunction and/or gastrointestinal tract disorders
USPP22355P3 (en) * 2009-06-30 2011-12-20 Zespri Group Limited Kiwifruit plant named ‘ZESY002’
PL2528610T3 (pl) * 2010-01-28 2014-02-28 Ab Biotics Sa Kompozycja probiotyczna do zastosowania w leczeniu zapalenia jelita
CA2967263A1 (en) * 2014-11-28 2016-06-02 Anagenix Ip Limited Gold kiwifruit compositions and methods of preparation and use therefor

Also Published As

Publication number Publication date
US20220105145A1 (en) 2022-04-07
US20170326190A1 (en) 2017-11-16
US20240091291A1 (en) 2024-03-21
CN116763830A (zh) 2023-09-19
NZ769769A (en) 2024-07-26
EP3223838A4 (en) 2018-08-01
EP4548775A2 (en) 2025-05-07
EP3223838A1 (en) 2017-10-04
KR102599549B1 (ko) 2023-11-06
JP2017537156A (ja) 2017-12-14
NZ732197A (en) 2022-07-01
EP4548775A3 (en) 2025-08-27
EP3223838B1 (en) 2025-02-05
US11090348B2 (en) 2021-08-17
JP7330667B2 (ja) 2023-08-22
CN116270773A (zh) 2023-06-23
PL3223838T3 (pl) 2025-05-26
US11642386B2 (en) 2023-05-09
BR112017011078A2 (pt) 2017-12-26
SI3223838T1 (sl) 2025-07-31
JP7471668B2 (ja) 2024-04-22
KR20230156436A (ko) 2023-11-14
CN106999523A (zh) 2017-08-01
FI3223838T3 (fi) 2025-05-05
KR20170088970A (ko) 2017-08-02
DK3223838T3 (da) 2025-04-28
WO2016085356A1 (en) 2016-06-02
CA2967263A1 (en) 2016-06-02
PT3223838T (pt) 2025-04-28
ES3023661T3 (en) 2025-06-02
FI3223838T8 (fi) 2025-06-16
CA3200468A1 (en) 2016-06-02
JP2024088715A (ja) 2024-07-02
JP2022078050A (ja) 2022-05-24
US10512663B2 (en) 2019-12-24
MY188290A (en) 2021-11-25
US20200197460A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
US11642386B2 (en) Gold kiwifruit compositions and methods of preparation and use therefor
Xiao et al. Lactic acid bacteria in health and disease
KR102825170B1 (ko) 프로바이오틱 비피도박테리움 브레베 균주 및 상기 균주를 포함하는 조성물
JP7360420B2 (ja) ディスバイオシスの治療のために用いられるブドウ果皮
US20240293483A1 (en) Probiotic composition for the treatment of increased intestinal permeability
US20100143319A1 (en) Kiwifruit compositions
KR102641644B1 (ko) 락토바실러스 플란타룸의 치료적 용도
KR20240038015A (ko) 신생아의 치료에서 락토바실러스 파라카세이 박테리아 균주의 용도
US20250170163A1 (en) Compositions and methods for reducing the occurrence of diarrhea by promoting blautia obeum in the gut microbiota
SP Effects of Resveratrol in a Mouse Model of Alcohol Addiction
CN118613177A (zh) 通过促进肠道微生物群中的卵形布劳特氏菌来降低痢疾发生率的组合物和方法
HK40065763A (zh) 产生短链脂肪酸的益生菌菌株和包含该益生菌菌株的组合物

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/11/2015, OBSERVADAS AS CONDICOES LEGAIS.